Replimune vs BeOne Medicines: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Replimune Group Inc (REPL)

Q3 202623 Jun – 11 Aug 2026

▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.
This was the key regulatory catalyst that drove the stock's massive jump.
Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.
This approval is a major milestone that transforms the company's business prospects.
Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.
These investigations pose a legal overhang that could weigh on the stock.
Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.
The offering dilutes current shareholders and can pressure the share price.

July 202623 Jun – 11 Aug 2026

▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.
This was the key regulatory catalyst that drove the stock's massive jump.
Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.
This approval is a major milestone that transforms the company's business prospects.
Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.
These investigations pose a legal overhang that could weigh on the stock.
Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.
The offering dilutes current shareholders and can pressure the share price.

Latest23 Jun – 11 Aug 2026

▲2▼2

FDA approves Replimune's first drug, then company raises $150M

FDA grants accelerated approval for Tudriqev The FDA granted accelerated approval to Replimune's Tudriqev combined with Opdivo for advanced melanoma, based on a 24.2% response rate. This is the company's first commercial product, turning it from a clinical-stage hopeful into a revenue-generating business and lifting the stock.
This is the single biggest new event: approval validates the drug and opens a path to sales.
Securities fraud investigation expands to Pomerantz Pomerantz LLP opened an investigation into whether Replimune misled investors before the FDA's July 28 briefing documents questioned the RP1 data. This adds to earlier law firm probes, keeping a legal cloud over the stock and potentially weighing on the price.
It is a new law firm joining the investigation, adding fresh negative pressure.
$150 million stock offering dilutes shareholders Replimune priced a $150 million stock sale at $12.06 per share, issuing about 9.7 million new shares. This raises cash to launch Tudriqev but dilutes existing investors' ownership, which typically pushes the stock down in the short term.
It is a new financing event that directly affects share count and cash position.
FDA flexibility and biotech rally support Replimune The FDA signaled a more flexible approval approach for serious diseases, opening new pathways for Replimune and others. This supportive regulatory backdrop helped biotech stocks broadly and made RP1's eventual approval more likely, lifting sentiment around Replimune.
It explains the favorable regulatory environment that helped Replimune's path to approval.

30 Jul – 31 Jul 2026

▲2▼1

FDA panel backs RP1, reversing prior briefing-document collapse

FDA advisory panel votes 10-3 in favor of RP1 An FDA advisory committee voted 10 to 3 that RP1's single-arm IGNYTE study results are evaluable and clinically meaningful for advanced melanoma. This removes the main regulatory doubt and makes approval by the August 2 target date far more likely, pushing the stock sharply higher.
This is the core new event that flipped sentiment and drove the huge price jump.
Stock surges over 130% premarket, analyst upgrade Replimune shares soared more than 130% before the open and were up about 94-125% during the day after the panel vote. Wedbush upgraded the stock to outperform from neutral, a sign that professional investors now see the approval path as much clearer.
Shows the market's immediate, large positive reaction and a key analyst endorsement.
Securities fraud investigations launched Two law firms, Kirby McInerney and Bragar Eagel & Squire, opened investigations into whether Replimune misled investors before the FDA's July 28 briefing documents called the RP1 study non-interpretable. No lawsuit has been filed yet, but this legal cloud could weigh on the stock.
A real counterweight that could hurt the stock even after the positive panel vote.

BeOne Medicines AG (6160.HK)

Q3 202620 Jun – 2 Sep 2026

▲3▼1

BeOne Q3: Pipeline Wins, US Investment, But Pricing Deal Looms

BRUKINSA Phase 3 Wins and Solid Tumor Progress BRUKINSA scored Phase 3 wins in CLL and mantle cell lymphoma, reinforcing its core status. Three solid-tumor programs advanced toward pivotal trials, prompting analyst price-target hikes.
This point highlights the clinical and pipeline successes that drove positive sentiment and analyst upgrades.
US Manufacturing Investment and Strong Q2 Revenue BeOne invested $1 billion in U.S. manufacturing and reported Q2 revenue up 30% with raised guidance, signaling confidence in growth and supply chain expansion.
This point captures the financial and operational investments that supported the stock's positive momentum.
FDA Approval and Positive Survival Data for TEVIMBRA/ZIIHERA The FDA approved TEVIMBRA plus ZIIHERA for HER2+ gastroesophageal cancer, and HERIZON-GEA-01 showed positive survival data, expanding treatment options.
This point underscores regulatory and clinical milestones that open new market opportunities.
CEO Stock Sale and US Pricing Agreement The CEO sold $34.6 million in stock under a pre-set plan, though he retains over 50 million shares. A U.S. pricing agreement traded tariff relief for Medicaid discounts and lower prices, potentially pressuring future revenue.
This point presents the main counterweights that could temper positive developments.

August 202612 Aug – 2 Sep 2026

▲3

BeOne's strong Q2, new drug approvals, and US pricing deal shape outlook

Q2 revenue jumps 30%, guidance raised BeOne reported Q2 revenue of $1.7 billion, up 30% from a year ago, with earnings per share up 144%. The company raised its full-year revenue and profit guidance and doubled free cash flow. This shows the business is growing strongly and has more money to invest in new drugs, which supports a higher stock price.
This is the core financial update that directly boosts investor confidence and the stock's value.
FDA approves TEVIMBRA combo for HER2+ cancer The FDA approved BeOne's TEVIMBRA combined with ZIIHERA and chemotherapy for first-line HER2-positive gastroesophageal cancer. This is a new treatment option for a cancer affecting over 31,000 Americans yearly. The approval opens a new revenue stream and validates the company's research, pushing the stock up.
A new regulatory approval directly expands the company's marketable products and future sales.
Positive Phase 3 survival data for ZIIHERA regimens BeOne announced positive topline results from the Phase 3 HERIZON-GEA-01 trial, showing ZIIHERA plus chemotherapy significantly improved overall survival in first-line HER2+ gastroesophageal adenocarcinoma. Longer follow-up for the TEVIMBRA plus ZIIHERA regimen also showed durable outcomes. Strong data increases confidence in the drug's commercial success.
Strong clinical trial results support the drug's efficacy and potential for wider use, lifting the stock.
US pricing deal: tariff relief but price discounts BeOne signed a voluntary agreement with the US government to expand cancer drug access, including participation in the GENEROUS Model and Medicaid discounts, in exchange for exemption from Section 232 pharmaceutical tariffs. While this avoids costly tariffs and supports US manufacturing, it also means lower prices for some drugs, which could pressure future revenue.
This is a major regulatory and pricing development that has both positive (tariff exemption) and negative (price cuts) implications for the stock.

Latest12 Aug – 2 Sep 2026

▲3

BeOne's strong Q2, new drug approvals, and US pricing deal shape outlook

Q2 revenue jumps 30%, guidance raised BeOne reported Q2 revenue of $1.7 billion, up 30% from a year ago, with earnings per share up 144%. The company raised its full-year revenue and profit guidance and doubled free cash flow. This shows the business is growing strongly and has more money to invest in new drugs, which supports a higher stock price.
This is the core financial update that directly boosts investor confidence and the stock's value.
FDA approves TEVIMBRA combo for HER2+ cancer The FDA approved BeOne's TEVIMBRA combined with ZIIHERA and chemotherapy for first-line HER2-positive gastroesophageal cancer. This is a new treatment option for a cancer affecting over 31,000 Americans yearly. The approval opens a new revenue stream and validates the company's research, pushing the stock up.
A new regulatory approval directly expands the company's marketable products and future sales.
Positive Phase 3 survival data for ZIIHERA regimens BeOne announced positive topline results from the Phase 3 HERIZON-GEA-01 trial, showing ZIIHERA plus chemotherapy significantly improved overall survival in first-line HER2+ gastroesophageal adenocarcinoma. Longer follow-up for the TEVIMBRA plus ZIIHERA regimen also showed durable outcomes. Strong data increases confidence in the drug's commercial success.
Strong clinical trial results support the drug's efficacy and potential for wider use, lifting the stock.
US pricing deal: tariff relief but price discounts BeOne signed a voluntary agreement with the US government to expand cancer drug access, including participation in the GENEROUS Model and Medicaid discounts, in exchange for exemption from Section 232 pharmaceutical tariffs. While this avoids costly tariffs and supports US manufacturing, it also means lower prices for some drugs, which could pressure future revenue.
This is a major regulatory and pricing development that has both positive (tariff exemption) and negative (price cuts) implications for the stock.

July 202620 Jun – 23 Jul 2026

▲3

BeOne's pipeline and BRUKINSA data drive gains; CEO sale and US expansion in focus

BRUKINSA Phase 3 wins in two blood cancers Updated SEQUOIA data showed BRUKINSA kept 71.8% of CLL patients progression-free at 78 months versus 31% for standard chemo. Separately, the MANGROVE trial in frontline mantle cell lymphoma cut progression or death risk by 43%. These strengthen BRUKINSA as a foundational therapy and support future sales growth.
Directly boosts confidence in the company's biggest selling drug and its expansion into new uses.
Three new cancer drugs advance toward pivotal trials At ASCO 2026, BeOne presented promising data for three solid-tumor programs: BGB-43395 for breast cancer, BG-C9074 for ovarian cancer, and BGB-B2033 for liver cancer. All target areas with high unmet need. Analysts called it an inflection point, raising price targets to as high as $436.
Shows the company is building a broader pipeline beyond BRUKINSA, which could drive future revenue.
CEO sells $34.6 million in stock under pre-set plan CEO John Oyler sold 109,713 shares for $34.6 million under a trading plan adopted in March 2026. He still holds over 50 million shares, so the sale is a tiny fraction of his stake. Such sales can spook investors, but the pre-set nature and his large remaining holding soften the blow.
A potential negative signal that is largely neutralized by the pre-planned nature and small size relative to his holdings.
BeOne invests $1 billion in U.S. manufacturing BeOne is expanding its New Jersey site with a $300 million addition, bringing total U.S. investment to over $1 billion. The new facility will make small-molecule drugs and add 120 jobs. This supports its pipeline of 35+ assets and may ease supply and regulatory risks.
Strengthens domestic production capacity, which can support future sales and reduce reliance on overseas manufacturing.

20 Jun – 23 Jul 2026

▲3

BeOne's pipeline and BRUKINSA data drive gains; CEO sale and US expansion in focus

BRUKINSA Phase 3 wins in two blood cancers Updated SEQUOIA data showed BRUKINSA kept 71.8% of CLL patients progression-free at 78 months versus 31% for standard chemo. Separately, the MANGROVE trial in frontline mantle cell lymphoma cut progression or death risk by 43%. These strengthen BRUKINSA as a foundational therapy and support future sales growth.
Directly boosts confidence in the company's biggest selling drug and its expansion into new uses.
Three new cancer drugs advance toward pivotal trials At ASCO 2026, BeOne presented promising data for three solid-tumor programs: BGB-43395 for breast cancer, BG-C9074 for ovarian cancer, and BGB-B2033 for liver cancer. All target areas with high unmet need. Analysts called it an inflection point, raising price targets to as high as $436.
Shows the company is building a broader pipeline beyond BRUKINSA, which could drive future revenue.
CEO sells $34.6 million in stock under pre-set plan CEO John Oyler sold 109,713 shares for $34.6 million under a trading plan adopted in March 2026. He still holds over 50 million shares, so the sale is a tiny fraction of his stake. Such sales can spook investors, but the pre-set nature and his large remaining holding soften the blow.
A potential negative signal that is largely neutralized by the pre-planned nature and small size relative to his holdings.
BeOne invests $1 billion in U.S. manufacturing BeOne is expanding its New Jersey site with a $300 million addition, bringing total U.S. investment to over $1 billion. The new facility will make small-molecule drugs and add 120 jobs. This supports its pipeline of 35+ assets and may ease supply and regulatory risks.
Strengthens domestic production capacity, which can support future sales and reduce reliance on overseas manufacturing.